Identification of COVID-19 subtypes based on immunogenomic profiling

Area of Science:

• Immunology
• Infectious Diseases
• COVID-19 Research

Background:

• Host immune response significantly influences COVID-19 patient outcomes.
• Specific associations between immune signatures and clinical outcomes require further elucidation.

Purpose of the Study:

• To identify distinct COVID-19 patient subtypes based on immune signatures.
• To investigate the relationship between these immune subtypes and clinical outcomes.
• To explore the differential impact of innate versus adaptive immunity on disease severity.

Main Methods:

• Clustering analysis of 11 immune signatures (8 immune-inciting, 3 immune-inhibiting) in leukocytes from 100 COVID-19 patients.
• Comparison of clinical outcomes across identified COVID-19 immune subtypes (Im-C1, Im-C2, Im-C3).
• Assessment of the relative contributions of adaptive and innate immune responses to patient outcomes.

Main Results:

• Three COVID-19 immune subtypes were identified: Im-C1 (low immune-inciting, high immune-inhibiting), Im-C2 (medium immune-inciting, high immune-inhibiting), and Im-C3 (high immune-inciting, low immune-inhibiting).
• Im-C3 patients exhibited the best clinical outcomes, while Im-C1 patients had the worst, indicating a protective role for antiviral immune responses.
• Adaptive immune responses demonstrated a greater impact on COVID-19 outcomes than innate immune responses. Younger patients showed stronger antiviral responses. Type II Interferon (IFN) response was identified as an adverse prognostic factor.

Conclusions:

• Distinct COVID-19 immune subtypes correlate with varying clinical outcomes.
• A robust antiviral immune response, particularly adaptive immunity, is associated with improved prognosis in COVID-19.
• These findings offer potential clinical implications for stratifying and managing COVID-19 patients based on their immune profiles.